There is provided a method of manufacturing silica microspheres includes the steps of mixing acid and water to form a mixture; adding a silicon alkoxide to the mixture so as to precipitate microspheres; allowing the microspheres to settle into a sediment and removing a supernatant liquid; and immersing the microspheres in acid.

The invention relates generally to a formulation in which metal tungstate or metal molybdate particles are encapsulated within biocompatible, diseased cell-targeting polymeric coatings. Such formulations render metal tungstate or metal molybdate particles suitable for in vivo biomedical imaging and therapeutic applications.

The present invention relates to a gold nanoparticle-containing medicine, and a treatment of a proliferative disease using the medicine. The present invention also relates to a gold nanoparticle-containing medicine that is bound to an alpha radioactive nucleus, and a treatment of a proliferative disease using the medicine.

Described herein are nanoprobes comprising ultrasmall aminated and cRGDY-conjugated nanoparticles labeled with Zirconium-89 (.sup.89Zr) and methods of their use. The provided compositions are renally clearable and possess suitable blood circulation half-time, high tumor active targeting capability, dominant renal clearance, low liver accumulation, and a high tumor-to-background ratio. The described nanoprobes exhibit great potential as “target-or-clear” tracers to human subjects for systemic targeted imaging (or treatment) of cancer.

A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.

The present disclosure provides EBNA1 and LMP1 dual-targeting peptides and upconversion nanoparticles conjugates comprising the same useful as therapeutic and theranostic agents capable of targeting EBNA1 and LMP1 proteins present in Epstein-Barr virus infected cells, such as cancer.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.

A nanoparticle comprising chemically modified heparin, wherein the heparin has been chemically modified by attaching hydrophobic moieties to functional groups of the heparin, said functional groups being selected from hydroxy groups and carboxy groups, for use in the treatment or diagnosis of a brain disorder.

A method of distributing microparticles is provided, the method comprising: providing a plurality of microparticles at an insertion site in a medium; applying ultrasound to the insertion site that generates gas bubbles by cavitation at cavitation nuclei located at the insertion site and drives movement of the gas bubbles such that the gas bubbles drive movement of the microparticles into a desired spatial distribution in the tumour. The method may be a method of treating a tumour, and the microparticles may comprise a radioisotope for treating the tumour. Microparticles for use in the treatment of a tumour by the method are also disclosed.